Skip to content
etf.net

Launched · SEC filings

Corgi ETF Trust I - Corgi Genomics & Precision Medicine ETF

GNMXCboeC

$36.33−0.43 (−1.16%)

As of Oct 13, 2026, 3:28 PM

C40/ 100

Rank 11 of 17 in Biotech & Genomics

C40/100Rank 11 of 17inBiotech & Genomics
Intraday session: down, 9 prints from 36.76 to 36.33. Range 36.14 to 36.76. Use the arrow keys to read each point.36.2036.4036.5036.6010 AM12 PM2 PM4 PM
Expense ratio
0.35%
Fund size
$1M
1Y total return
—
Yield · Last 12 months
—
Holdings
58
Avg volume · 30D
0M sh
NAV per share
$37.50
52W range
low $23.88high $39.65
Launched
Filings
SEC EDGAR

The ETF.net GNMX Grade

Based on 5 of 6 pillars

C

Score 40 out of 100

Category
Biotech & Genomics⁠
Rank
11 of 17
Six-pillar profile for GNMX. Scores out of 100: Cost 81, Risk 79, Mission not scored, Tradability 9, Holdings 50, Durability 0. Strongest: Cost (81). Weakest: Durability (0). Based on 5 of 6 pillars.

Score 40 of 100 falls in the C band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

Very small fund, grade capped at C.

The cap holds the Score at 40 or below, so B and A are out of reach.

The pillars earned
57
This cap took
−17
Published Score
40 Grade C

  • Cost

    The fund’s net expense ratio, ranked against its category.
    A81 out of 100
    Rank 3 of 17

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    Not scored

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    A79 out of 100
    Rank 1 of 17

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    F9 out of 100
    Rank 16 of 17

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    C50 out of 100
    Rank 10 of 17

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    F0 out of 100
    Rank 17 of 17

GNMX Holdings

As of Oct 13, 2026
Asset class
Stocks
Holdings
58
Top-10 weight
48%
Largest holding
MRNA9.7%

Sectors

  • Health Care97.7%
  • Technology2.3%

Geography

  • United States92.10%
  • Denmark3.12%
  • Netherlands2.84%
  • Switzerland1.93%
The fund’s holdings, weight-ordered — page 1 of 4.
#TickerCompanyWeight %SharesMarket valueIn ETFs
001MRNAModerna Inc9.65%581$124K286
002TMOThermo Fisher Scientific Inc8.65%168$111K375
003VRTXVertex Pharmaceuticals Inc5.79%147$75K422
004ILMNIllumina Inc4.97%231$64K322
005GHGuardant Health Inc3.46%273$44K175
006TXG10X Genomics Inc3.31%567$43K137
007RVMDRevolution Medicines Inc3.27%217$42K176
008IOVAIovance Biotherapeutics Inc3.23%2,849$41K91
009GMABGenmab A/S3.09%1,064$40K28
010—First American Government Obligations Fund 12/01/20312.57%33,037$33K529
011TWSTTwist Bioscience Corp2.56%217$33K125
012INCYIncyte Corp2.55%294$33K372
013ALNYAlnylam Pharmaceuticals Inc2.47%140$32K259
014GRALGRAIL Inc2.24%210$29K85
015TECHBio-Techne Corp2.17%385$28K186

Showing 1–15 of 58 holdings

GNMX Performance

Launched May 5, 2026

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

Not enough history yet.Not enough history yet.Not enough history yet.Not enough history yet.Not enough history yet.
GNMX$11,858
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$10,332
Jul 10, 2026 to Oct 12, 2026. GNMX $11,858. SPY $10,332. Use the arrow keys to read each point.$9,290$11,092$12,894Jul 2026Aug 2026Oct 2026

Jul 10, 2026 – Oct 12, 2026

Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for GNMX. Periods over one year show the average yearly return.
PeriodGNMX
Year to dateFund launched this year—
1 month+7.6%
3 months+18.6%
1 yearFund is under 1 year old—
3 yearsFund is under 3 years oldper year—
5 yearsFund is under 5 years oldper year—
10 yearsFund is under 10 years oldper year—

As of the close, with distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for GNMX
YearReturn barGNMX
2026 YTD+43.0%

History from May 6, 2026

GNMX in the news

Filtered to GNMX · Biotech & Genomics

GNMX Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 12, 2026.
—Last 12 months
Payout per share
—Last 12 months

Listed May 2026. No distributions yet.

GNMX Risk

How much the fund’s monthly returns vary, scaled to a year.
—
Launched May 2026; fills in after 12 months
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
—
Launched May 2026; fills in after 12 months
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
—
Launched May 2026; fills in after 12 months
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
2.27
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

GNMX Cost

Expense ratio0.35%
  • The middle half of Biotech & Genomics funds
  • Median 0.47%

2 of the 17 Biotech & Genomics funds charge less.

GNMX costs $35.00 a year on $10,000. The median Biotech & Genomics fund costs $47.00.

Other funds in Biotech & Genomics

See others